Govt panel recommends market authorisation for Covovax jab as booster dose

Covovax is manufactured through technology transfer from Novavax

vaccine
In August 2020, US-based vaccine maker Novavax Inc. had announced a licence agreement with SII for development and commercialization of NVX-CoV2373, its COVID-19 vaccine candidate in India and low-and-middle-income countries
Press Trust of India New Delhi
2 min read Last Updated : Jan 12 2023 | 7:10 PM IST

An expert panel of the central drug regulatory authority has recommended market authorisation for Serum Institute of India's Covid vaccine Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin, official sources said on Thursday.

Prakash Kumar Singh, director (government and regulatory affairs) at Serum Institute of India (SII) had recently written a letter to Drugs Controller General of India (DCGI) for approval of Covovax heterologous booster dose for those aged 18 years and above in view of escalating COVID-19 pandemic situation in some countries, the sources said.

"The subject expert committee (SEC) of the CDSCO on Wednesday deliberated on the issue and recommended for market authorisation of Covid jab Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin," an official source said.

The DCGI had approved Covovax for restricted use in emergency situations in adults on December 28, 2021, in the 12-17 age group on March 9, 2022 and also in children aged 7-11 years on June 28, 2022 subject to certain conditions.

Covovax is manufactured through technology transfer from Novavax. It has been approved by the European Medicines Agency for conditional marketing authorization. It was granted emergency-use listing by the World Health Organization (WHO) on December 17, 2021.

In August 2020, US-based vaccine maker Novavax Inc. had announced a licence agreement with SII for development and commercialization of NVX-CoV2373, its COVID-19 vaccine candidate in India and low-and-middle-income countries.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusDelta variant of coronavirusCoronavirus VaccineCoronavirus Tests

First Published: Jan 12 2023 | 7:10 PM IST

Next Story